| 1 |
Arafat HM. A comprehensive review of immune checkpoint inhibitors for cancer treatment[J]. Int Immunopharmacol, 2024, 143(Pt 2):113365.
|
| 2 |
Butterfield LH, Najjar YG. Immunotherapy combination approaches:mechanisms, biomarkers and clinical observations[J]. Nat Rev Immunol, 2024, 24(6):399-416.
|
| 3 |
Xin Yu J, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global[J]. Nature Reviews Drug Discovery, 2019,18(12):899-900.
|
| 4 |
樊勇, 耿研, 赵娟, 等. 免疫检查点抑制剂相关风湿免疫病表现及管理[J]. 中国医学前沿杂志（电子版）, 2022, 14(8):6-10.
|
| 5 |
高君伟, 刘皋林. 自身免疫性疾病的药物治疗 [J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1209-1211.
|
| 6 |
Fan Y, Geng Y, Shen L et al. Advances on immune-related adverse events associated with immune checkpoint inhibitors[J]. Frontiers of Medicine, 2021, 15(1):33-42.
|
| 7 |
Ramos-Casals M, Siso-Almirall A. Immune-Related Adverse Events of Immune Checkpoint Inhibitors[J]. Ann Intern Med, 2024,177(2):ITC17-ITC32.
|
| 8 |
Khan SA, Pruitt SL, Xuan L et al. Prevalence of Autoimmune Disease Among Patients With Lung Cancer[J]. JAMA Oncology, 2016,2(11):1507.
|
| 9 |
van der Kooij MK, Suijkerbuijk KPM, Aarts MJB et al. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease[J]. Annals of Internal Medicine,2021, 174(5):641-648.
|
| 10 |
Menzies AM, Johnson DB, Ramanujam S et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab[J]. Annals of Oncology,2017, 28(2):368-376.
|
| 11 |
Abdel-Wahab N, Shah M, Lopez-Olivo MA et al. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease[J]. Annals of Internal Medicine,2018, 168(2):121.
|
| 12 |
Danlos F, Voisin A, Dyevre V et al. Safety and efficacy of antiprogrammed death 1 antibodies in patients with cancer and preexisting autoimmune or inflammatory disease[J]. European Journal of Cancer, 2018, 91:21-29.
|
| 13 |
Leonardi GC, Gainor JF, Altan M et al. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders[J]. J Clin Oncol, 2018,36(19):1905-1912.
|
| 14 |
Tison A, Quéré G, Misery L, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study[J].Arthritis & Rheumatology, 2019, 71(12):2100-2111.
|
| 15 |
Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease [J]. Journal of Clinical Oncology, 2020, 38(6):576-583.
|
| 16 |
Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N et al. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease[J]. Eur J Cancer, 2024,207:114148.
|
| 17 |
Rzeniewicz K, Larkin J, Menzies AM et al. Immunotherapy use outside clinical trial populations: never say never?[J]. Ann Oncol,2021, 32(7):866-880.
|
| 18 |
Liu X, Li S, Ke L, et al. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases:a systematic review and meta-analysis[J]. BMC Cancer, 2024,24(1):490.
|
| 19 |
Tang H, Zhou J, Bai C. The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease[J]. Frontiers in Oncology, 2021, 11: 625872.
|
| 20 |
Reid P, Sandigursky S, Song J et al. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases[J]. Oncoimmunology,2023, 12(1):2261264.
|
| 21 |
Thompson JA, Schneider BJ, Brahmer J et al. NCCN Guidelines(R)Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024[J]. J Natl Compr Canc Netw, 2024, 22(9):582-592.
|
| 22 |
Arbour KC, Mezquita L, Long N et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer[J]. Journal of Clinical Oncology, 2018, 36(28):2872-2878.
|
| 23 |
Ricciuti B, Dahlberg SE, Adeni A et al. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications[J]. Journal of Clinical Oncology, 2019, 37(22):1927-1934.
|
| 24 |
Bai X, Hu J, Betof Warner A et al. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy[J]. Clinical Cancer Research, 2021, 27(21):5993-6000.
|
| 25 |
Carbone DP, Reck M, Paz-Ares L et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. New England Journal of Medicine, 2017, 376(25):2415-2426.
|
| 26 |
Schneider BJ, Naidoo J, Santomasso BD et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update[J]. Journal of Clinical Oncology, 2021, 39(36):4073-4126.
|
| 27 |
Libert C, Dejager L. How Steroids Steer T Cells[J]. Cell Reports,2014, 7(4):938-939.
|
| 28 |
Gruver-Yates A, Cidlowski J. Tissue-Specific Actions of Glucocorticoids on Apoptosis: A Double-Edged Sword[J]. Cells, 2013,2(2):202-223.
|
| 29 |
Tokunaga A, Sugiyama D, Maeda Y et al. Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids[J]. Journal of Experimental Medicine, 2019, 216(12):2701-2713.
|
| 30 |
Haanen J, Ernstoff MS, Wang Y et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy[J]. Ann Oncol, 2020, 31(6):724-744.
|
| 31 |
Frohne CC, Llano EM, Perkovic A et al. Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies[J]. Journal for ImmunoTherapy of Cancer, 2019, 7(1):1.
|
| 32 |
Uemura M, Trinh VA, Haymaker C et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report[J]. Journal of Hematology &Oncology, 2016, 9(1):81.
|
| 33 |
Martins F, Sykiotis GP, Maillard M et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities[J]. The Lancet Oncology, 2019, 20(1):e54-e64.
|
| 34 |
Henderson BM, Del RS, Miller WH. Potential therapies for immunerelated adverse events associated with immune checkpoint inhibition:from monoclonal antibodies to kinase inhibition[J]. J Immunother Cancer, 2022, 10(1).
|
| 35 |
Rose N, Furer V, Polachek A et al. Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy[J]. Eur J Rheumatol, 2024, 11(1):27-32.
|
| 36 |
Wang M, Chen S, He X et al. Targeting inflammation as cancer therapy[J]. J Hematol Oncol, 2024, 17(1):13.
|
| 37 |
Kang JH, Bluestone JA, Young A. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines[J]. Trends in Immunology, 2021, 42(4):293-311.
|
| 38 |
Perez-Ruiz E, Minute L, Otano I et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy[J]. Nature, 2019, 569(7756):428-432.
|